Clinical Trials Logo

Arsenical Keratosis clinical trials

View clinical trials related to Arsenical Keratosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT03127670 Completed - Arsenical Keratosis Clinical Trials

Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion

Start date: November 14, 2016
Phase: Phase 2
Study type: Interventional

Solanum melongena is a common vegetable contains phytochemicals which prevent, reduce or delay the oxidation of DNA and alter the cellular signal transduction pathways controlling cell proliferation and apoptosis of human cancer. The skin of Solanum melongena peel contains nasunin an anthocyanins and chlorogenic acid which have anti-inflammatory, antioxidant, antimutagenic and antiangiogenic properties. Extract of Solanum melongena is used in actinic keratosis and Squamous cell carcinoma of the skin. This study will determine any change in arsenical skin lesion after administrating Solanum melongena extract cream.

NCT ID: NCT01752972 Completed - Arsenical Keratosis Clinical Trials

Effect of Spirulina on Zinc, Vitamin E and Linoleic Acid Levels in Palm Skin Following Chronic Exposure to Arsenic

Start date: April 2011
Phase: N/A
Study type: Interventional

Patients of arsenical keratosis may be treated with spirulina. Is this improvement related to the levels of zinc, vitamin E and linoleic acid at the site of the keratosis (palm)? To understand this, patients of palmer arsenical keratosis (n=10), arsenic exposed controls (n=10) and healthy volunteers (n=10) will be treated with spirulina powder 10 g/day orally for 12 weeks. Skin extracts will be collected both before and after supplementation from the palm and dorsum for estimation of zinc, vitamin E and linoleic acid levels.

NCT ID: NCT01735097 Completed - Arsenical Keratosis Clinical Trials

Effect of Nigella Sativa in the Treatment of Palmer Arsenical Keratosis

Start date: January 2013
Phase: N/A
Study type: Interventional

Daily intake of Nigella sativa for 12 weeks is effective in the treatment of palmer arsenical keratosis

NCT ID: NCT01731756 Completed - Arsenical Keratosis Clinical Trials

Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis

Start date: January 2013
Phase: N/A
Study type: Interventional

Effects of leaf extract of Azadirachta indica in palmer arsenical keratosis: Randomized, double-blind, placebo-control trial

NCT ID: NCT01442727 Completed - Arsenical Keratosis Clinical Trials

Selenium in the Treatment of Arsenic Toxicity and Cancers

SETAC
Start date: December 2006
Phase: Phase 3
Study type: Interventional

Context: Approximately 100 million people throughout the world consume water contaminated with arsenic at levels above carcinogenic thresholds, including 40 million in Bangladesh alone, with up to one-fourth of deaths attributed to arsenic exposure in the worst-affected regions. There are no proven therapies for treating chronic arsenic toxicity or for preventing arsenical cancers. Selenium has been known to counter arsenic toxicity in a variety of animal models. The investigators have recently shown in animals and humans that this effect is mediated by the formation of [(GS)2AsSe]- , the seleno-bis(S-glutathionyl) arsinium ion, which is then rapidly excreted via the hepatobiliary system. Concurrently, two Phase II studies in China and Bangladesh have suggested clinical benefit to selenium supplementation in arsenicosis patients. Objective: To assess whether daily selenium supplementation counters arsenic toxicity in patients exposed to drinking water arsenic. If proven effective, selenium supplementation might be safely and cost-effectively implemented in the worst-affected localities.